Qualification versus validation of biomarkers

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)

Abstract

The phases of research used to evaluate new drugs provide a useful reference point for determining the studies that need to be conducted to evaluate new biomarkers. However, biomarkers do not have a single pathway for changing health outcomes and may be used for a variety of purposes, such as improving diagnostic criteria, improving prognosis, improving the monitoring of disease or as a measurement of health outcomes. The impact on health outcomes is also less direct and is dependent on the sequence of actions taken as a consequence of the test results. The different purposes of biomarkers and the less direct effect on health outcomes require different study designs to those used for the evaluation of pharmaceutical products and a more careful interpretation of results. Greater collaboration between researchers designing laboratory-based qualification studies and researchers designing clinical validation studies could achieve a process of evaluation for biomarkers that is both reliable and efficient.

Original languageEnglish
Pages (from-to)40-43
Number of pages4
JournalScandinavian Journal of Clinical and Laboratory Investigation
Volume70
Issue numberSUPPL. 242
DOIs
Publication statusPublished - 2010

Fingerprint

Biomarkers
Health
Research Personnel
Validation Studies
Pharmaceutical Preparations
Monitoring
Research

Cite this

@article{d42be88e562e49feb54b4aded75655a3,
title = "Qualification versus validation of biomarkers",
abstract = "The phases of research used to evaluate new drugs provide a useful reference point for determining the studies that need to be conducted to evaluate new biomarkers. However, biomarkers do not have a single pathway for changing health outcomes and may be used for a variety of purposes, such as improving diagnostic criteria, improving prognosis, improving the monitoring of disease or as a measurement of health outcomes. The impact on health outcomes is also less direct and is dependent on the sequence of actions taken as a consequence of the test results. The different purposes of biomarkers and the less direct effect on health outcomes require different study designs to those used for the evaluation of pharmaceutical products and a more careful interpretation of results. Greater collaboration between researchers designing laboratory-based qualification studies and researchers designing clinical validation studies could achieve a process of evaluation for biomarkers that is both reliable and efficient.",
author = "Jenny Doust",
year = "2010",
doi = "10.3109/00365513.2010.493380",
language = "English",
volume = "70",
pages = "40--43",
journal = "Scandinavian Journal of Clinical and Laboratory Investigation",
issn = "0036-5513",
publisher = "Informa Healthcare USA",
number = "SUPPL. 242",

}

Qualification versus validation of biomarkers. / Doust, Jenny.

In: Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 70, No. SUPPL. 242, 2010, p. 40-43.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Qualification versus validation of biomarkers

AU - Doust, Jenny

PY - 2010

Y1 - 2010

N2 - The phases of research used to evaluate new drugs provide a useful reference point for determining the studies that need to be conducted to evaluate new biomarkers. However, biomarkers do not have a single pathway for changing health outcomes and may be used for a variety of purposes, such as improving diagnostic criteria, improving prognosis, improving the monitoring of disease or as a measurement of health outcomes. The impact on health outcomes is also less direct and is dependent on the sequence of actions taken as a consequence of the test results. The different purposes of biomarkers and the less direct effect on health outcomes require different study designs to those used for the evaluation of pharmaceutical products and a more careful interpretation of results. Greater collaboration between researchers designing laboratory-based qualification studies and researchers designing clinical validation studies could achieve a process of evaluation for biomarkers that is both reliable and efficient.

AB - The phases of research used to evaluate new drugs provide a useful reference point for determining the studies that need to be conducted to evaluate new biomarkers. However, biomarkers do not have a single pathway for changing health outcomes and may be used for a variety of purposes, such as improving diagnostic criteria, improving prognosis, improving the monitoring of disease or as a measurement of health outcomes. The impact on health outcomes is also less direct and is dependent on the sequence of actions taken as a consequence of the test results. The different purposes of biomarkers and the less direct effect on health outcomes require different study designs to those used for the evaluation of pharmaceutical products and a more careful interpretation of results. Greater collaboration between researchers designing laboratory-based qualification studies and researchers designing clinical validation studies could achieve a process of evaluation for biomarkers that is both reliable and efficient.

UR - http://www.scopus.com/inward/record.url?scp=77953162857&partnerID=8YFLogxK

U2 - 10.3109/00365513.2010.493380

DO - 10.3109/00365513.2010.493380

M3 - Article

VL - 70

SP - 40

EP - 43

JO - Scandinavian Journal of Clinical and Laboratory Investigation

JF - Scandinavian Journal of Clinical and Laboratory Investigation

SN - 0036-5513

IS - SUPPL. 242

ER -